Psomagen, Inc., previously named Macrogen Corp. in the U.S., was founded in 2004 as a subsidiary from Macrogen, Inc. of S. Korea. Macrogen, Inc. was established in 1997 and in its first year, the South Korean Ministry of Science and Technology selected the company to participate in a leading technology product on gene transplant and gene targeting. Since then, Macrogen has remained on the cutting edge of biotechnology.
In its early years of operation, Macrogen continued to work with the South Korean government, participating in gene transplants for the Ministry of Commerce, Industry and Energy and developing an anti-aging drug with the Ministry of Health and Welfare.
BREAKTHROUGHS IN THE EARLY 2000S
In 2000, Macrogen was the first bio venture company listed on KOSDAQ, a trading board of Korea Exchange in South Korea. The company was growing quickly. That year, it established the DNA Chip Support Center, which focused on research and development in the genomic analysis industry, as well as the Life Science Institute and Bioinformatics Institute.
Macrogen also became one of the first companies in the world to decode the genome of the microorganism Zymomonas, a critical element used in the production of ethanol. The sequence was later listed in the National Center for Biotechnology Information, and Macrogen partnered with Changhae Ethanol Co., Ltd. in 2006 to commercialize the Zymomonas strain for ethanol production.
The early 2000s brought more success for the company. Macrogen, in 2001, was the first Korean company to clone a mouse. In 2003, the company helped decode the genome information of Corynebacterium. It then developed a genome analysis chip that could be used to diagnose hereditary chromosome disorders. The Korea Food and Drug Administration approved its genome analysis chip in 2006, and the chip has since been honored at the Health Industry Technology Exhibition.See more